Recently Featured

Arvinas, Pfizer Secure New Partner for Veppanu, Addressing Financial Uncertainties

May 20, 2026
A deal with Rigel Pharmaceuticals has been finalized, bringing clarity to the future of Veppanu, a newly approved breast cancer treatment that utilizes Protac technology. This partnership comes after months of speculation regarding the drug’s financial viability and market positioning. The collaboration with Rigel not only stabilizes Veppanu’s trajectory but also underscores the growing interest…

Isomorphic Labs Secures $2.1 Billion in Series B Funding, Reinforcing AI’s Role in Drug Discovery

May 20, 2026
Isomorphic Labs announced the successful closure of a $2.1 billion Series B funding round, underscoring its pivotal role in the integration of artificial intelligence within drug discovery processes. This significant financial milestone positions Isomorphic as a leader in the biotech sector, particularly notable as it marks the second-largest fundraising effort for a privately held biotech…

Bayer to Make ‘Careful but Aggressive’ Return to Pharma M&A, CEO Says

May 20, 2026
Bayer is poised to re-enter the pharmaceutical mergers and acquisitions landscape after a five-year hiatus, as confirmed by CEO Bill Anderson during a recent first-quarter earnings call. This strategic pivot marks a significant shift for the company, which has been largely inactive in the M&A space since its controversial acquisition of Monsanto in 2018. Anderson…

FDA Commissioner Marty Makary Resigns, Capping Turbulent Tenure: Report

May 20, 2026
Marty Makary, M.D., is resigning as FDA commissioner, effective Tuesday, following a brief and tumultuous tenure that has drawn significant criticism from various stakeholders within the pharmaceutical landscape. His departure comes amid ongoing debates regarding regulatory practices and the agency’s response to public health challenges, including the COVID-19 pandemic. This resignation underscores the increasing pressure…

Ongoing Cases